Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, health care giant Abbott Laboratories (NYSE: ABT ) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Abbott and see what CAPS investors are saying about the stock right now.
Abbott facts
| Headquarters (founded) | Abbott Park, Ill. (1888) |
| Market Cap | $58.9 billion |
| Industry | Health care equipment |
| Trailing-12-Month Revenue | $40 billion |
| Management | Chairman/CEO Miles White (since 1999) |
| Return on Equity (average, past 3 years) | 20.6% |
| Cash / Debt | $8.5 billion / $7.1 billion |
| Dividend Yield | 1.5% |
| Competitors | Boston Scientific |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 97% of the 2,617 members who have rated Abbott believe the stock will outperform the S&P 500 going forward.
Just last week, one of those Fools, cschweit, succinctly summed up the Abbott bull case for our community:
Undervalued stock as of right now. Biggest growth will come from emerging markets. Will need to deliver to those emerging markets if it will succeed -- which I think it can. A little worried about a major buyout of its major branches. ... Still a strong company with a good future.
10 Best Stocks To Buy Right Now
Abbott Labs has changed forever after losing its branded pharmaceutical business to a spinoff. If you're a current investor, or might be buying shares soon, make sure you truly understand the stock by reading The Motley Fool's brand new premium report on Abbott Labs. The report outlines all of the must-know opportunities and risks, along with a full year of analyst updates to keep you up to speed. Best of all, you can claim this report today by clicking here now.
No comments:
Post a Comment